As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. 

Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels, PhenoCycler®, PhenoImager® Fusion, and PhenoImager HT Instruments.

View our open job descriptions: www.akoyabio.com/careers

Follow us on Twitter: www.twitter.com/AkoyaBio   

Subscribe to our YouTube channel: www.youtube.com/c/AkoyaBiosciences 

Innovatus Capital Partners

Telegraph Hill Partners

Piper Jaffray Merchant Banking

Thomas Schnettler

Akoya Biosciences, Inc.

We are excited to welcome Crown Bioscience as an Akoya-qualified service provider! Headquartered in San Diego, CA, Crown Bioscience aims to support drug discovery through translational research across oncology and immuno-oncology.

By joining our Contract Research Organization Network, Crown Bioscience will utilize Akoya's Phenomager HT platform to offer advanced multispectral imaging technology, easily integrated into high-throughput workflows to accommodate projects regardless of scale.

Explore Crown Bioscience's digital pathology technologies: https://bit.ly/3T0ALxY

#oncology #immunooncology #drugdiscovery #phenoimager #crownbioscience

This groundbreaking study, published in Nature using our PhenoImager HT platform, offers a fresh perspective on the pathology and heterogeneity of rheumatoid arthritis. The findings hold promise for developing innovative targeted treatments for patients with this condition. 

🙌 Kudos to the authors for their valuable contribution to understanding this debilitating, autoimmune disease without a cure!

#FridayRead #PhenoImager #AkoyaInAction #SpatialBiology #RheumatoidArthritis

Join us at the Cancer Neuroscience Symposium at the MD Anderson Cancer Center in Houston, Texas!

The Akoya team will be there today and tomorrow and will be happy to discuss how our spatial biology solutions are making a difference in neuroscience and cancer research. 

Not attending? Explore our solutions on our website: https://bit.ly/47GvLFB

#SpatialBiology #Neuroscience #MDAnderson #CancerResearch #Immunology

Dr. Tom Lund and his team at the Integrated Pathology Unit (IPU) in London have consistently used our instruments, with the PhenoImager HT serving as a central resource in their laboratory.

The IPU, a collaborative effort between The Institute of Cancer Research and the Royal Marsden Hospital, is crucial in bridging clinical, translational, and basic research. Dr. Lund attributes the IPU's flexibility to their tissue-agnostic Akoya technology, which requires minimal tissue-specific optimization, allowing seamless adaptation to diverse research requirements.

We are thankful for Dr. Lund's ongoing support of our technology. We are excited to witness his lab's advancements in further understanding and treating cancer through multiplex immunofluorescence.

#spatialbiology #digitalpathology #multiplex #phenoimager SelectScience®

📢 Tomorrow is part 1 of a 2-part webinar series on fusing single-cell genomics and spatial proteomics with MaxFuse!

Hear Garry Nolan, Ph.D., discuss MaxFuse, a new AI algorithm that provides reliable, fast, and cost-effective integration of spatial proteomic data with single-cell transcriptomic and epigenomic datasets. 

This webinar will be offered at two different times on Feb 28th; attendees can join at 3 AM PT/6 AM ET/12 PM CET or 9 AM PT/12 PM ET/6 PM CET. 

Hope to see you there!

#spatialbiology #spatialproteomics #maxfuse #singlecell #genomics Genetic Engineering & Biotechnology News 

SSL by Default

Apple Mobile Web Clips Icon

Google Font API

HSTS

WordPress

Content Delivery Network

DoubleClick.Net

US Privacy User Signal Mechanism

DNSSEC

Brian Mckelligon

Joseph Driscoll

Chief People Officer

Marilee Moy

Board Member

Matt Winkler

Founder

Nikolay Samusik

Associate Director, ABS Scientific Liaisons

Amanda Esch

Global Market Development, Spatial Biology | Sales Executive @ Akoya Bio

Aniruddh Solanki

Director of Product Management

Anne Kwei

Senior Director, Controller

Branden Steinberg

Associate Director, RUO Systems Integration

Carla Coltharp

Matthew Winkler

Jack Fuchs

Ehab ElGabry

Chief Medical Officer

Brian McKelligon

Joseph S. Driscoll

Frederic Pla

Chief Operating Officer

Pascal Bamford

SVP ,Research and Development & Laboratory Operations

Garry Nolan

Yury Goltsev

Co-Founder

United States Public Companies With More Than 10 Employees

Northeastern US Companies With More Than 50 Employees (Top 10K)

Health Care Companies With Less Than $500M in Revenue (Top 10K)

Greater Boston Area Companies (Top 10K)

Akoya Biosciences is a spatial biology company offering the most comprehensive, end-to-end solutions for high-parameter tissue analysis from discovery through clinical and translational research, enabling the development of more precise therapies for immuno-oncology and other drug development applications. The company has two industry-leading platforms that empower investigators and researchers to gain a deeper understanding of complex diseases such as cancer, and autoimmune or neurological disorders. 

The CODEX system is the only benchtop platform that can efficiently quantify more than 40 biomarkers and is ideally suited for biomarker discovery. The Phenoptics platform is the only end-to-end multiplexed immunofluorescence solution with the robustness and high throughput necessary for translational research and clinical trials.

Post-IPO Equity - Akoya Biosciences

Series D - Akoya Biosciences

Venture Round - Akoya Biosciences

Computer and Software Products and Electrical and Scientific Products

Marlborough

Massachusetts

United States

North America

Akoya Biosciences

Akoya Biosciences names former molecular diagnostics CEO as new board chair

AKOYA BIOSCIENCES, INC.

Akoya Biosciences Reports Second Quarter 2024 Financial Results

BTIG cuts Akoya Biosciences stock rating amid revenue, staff concerns

Akoya Biosciences Further Trims Workforce, Lowers 2024 Guidance in Wake of Q2 Results

Akoya Biosciences just downgraded at JPMorgan, here's why

Morgan Stanley Downgrades Akoya Biosciences t...

Craig-Hallum Initiates Coverage of Akoya Biosciences With Buy Rating

Akoya Biosciences CEO Brian McKelligon sells $15,063 in stock

Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for ...

United Kingdom

Europe

China

Asia

Chile

South America

The Netherlands

HTML5

Facebook Comments

Adobe Fonts

GreenSock Animation Platform

Vimeo

Bootstrap

jQuery

Google Maps API

Wistia

Gravity Forms

Fluidigm is a biotechnology company that develops and manufactures innovative tools to empower life science research.

Fluidigm

NanoString is a provider of life science tools for translational research and molecular diagnostics.

NanoString

10x Genomics is a biotechnology company that develops products for scientific research in genomics.

10x Genomics

Caribou Biosciences Inc is a biotechnology company specializing in CRISPR genome editing technologies.

Caribou Biosciences Inc

Humacyte Inc is a biotechnology company focused on developing novel human acellular vessels for vascular repair and replacement.

Humacyte Inc

Akoya Biosciences, Inc. is a life sciences technology company that provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI.

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

news impact assignment basic	general	Mar 8, 2024 8:54 AM	a92d05b4
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 8, 2024 8:54 AM	e5055c41
company summary	general
signals	general	Mar 8, 2024 8:54 AM	bc54e557
crunchbase trigger	general	Oct 31, 2024 9:55 AM	e0ea6e7d
crunchbase profile	general	Oct 31, 2024 10:07 AM	d0c50278
li profile	general	Mar 8, 2024 8:54 AM	eeb2537d
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	316a5957
peers	general	Mar 8, 2024 8:54 AM	603254a7
news basic	general	Mar 8, 2024 8:54 AM	747b2ca8
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:AKOYABIO

Akoya Biosciences, Inc.

Last Close

2.12

22/11 21:00

Market Cap

102.72M

Beta: -

Volume Today

81.11K

Avg: -